Cargando…
Sensitive multiple myeloma disease monitoring by mass spectrometry
Autores principales: | Santockyte, Rasa, Jin, Chelsea, Pratt, James, Ammar, Ron, Desai, Keyur, Bolisetty, Mohan, Das, Prianka, Popa-McKiver, Mihaela, Puig, Oscar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084958/ https://www.ncbi.nlm.nih.gov/pubmed/33927186 http://dx.doi.org/10.1038/s41408-021-00473-9 |
Ejemplares similares
-
P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA
por: Piasecki, Julia, et al.
Publicado: (2023) -
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023) -
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2023) -
Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
por: Liu, Zhao-Yun, et al.
Publicado: (2023) -
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies
por: Armand, Philippe, et al.
Publicado: (2020)